O
PTCT icon

OppenheimerFunds’s PTC Therapeutics PTCT Stock Holding History

OppenheimerFunds’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-249,180
Closed -$12M – 971
2015
Q2 		$12M Sell
249,180
-49,020
-16% -$2.86M 0.01% 712
2015
Q1 		$18.1M Sell
298,200
-19,150
-6% -$1.17M 0.02% 618
2014
Q4 		$16.4M Buy
+317,350
New +$14M 0.02% 631

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

OppenheimerFunds's PTCT Position: Q3 2015 in Review

OppenheimerFunds sold out of PTC Therapeutics (PTCT) in Q3 2015, closing a stake of 249,180 shares — an estimated $12M sold.

OppenheimerFunds first reported a position in PTCT in Q4 2014 and held it in 3 quarters. The position peaked at $18.1M in Q1 2015. 157 funds tracked by Wall St. Rank hold PTCT as of Q3 2015.

  • OppenheimerFunds reported no remaining PTC Therapeutics position as of Q3 2015 after selling out during the quarter.
  • OppenheimerFunds sold 249,180 PTC Therapeutics shares in Q3 2015, an estimated $12M.
  • OppenheimerFunds first reported a position in PTC Therapeutics in Q4 2014 and held it in 3 quarters.
  • OppenheimerFunds's PTC Therapeutics position peaked at $18.1M in Q1 2015.
  • 157 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2015.

Based on OppenheimerFunds's 13F filing for Q3 2015, filed 6 Nov 2015.